Therapeutic vaccines for prostate cancer: a review of clinical data.
Prostate cancer is the most common, non-cutaneous cancer and the second leading cause of cancer death among men in the US. A greater understanding of basic immunological principles has led to the development of a variety of new techniques, which in turn has led to advances in the field of prostate cancer vaccines. This review will discuss the rationale for the development of vaccines involving whole tumor cells and dendritic cells, as well as pox viral vectors, and will summarize selected clinical studies that have incorporated these strategies.
Arlen
Philip M
PM
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892-1750, USA. pa52s@nih.gov
Gulley
James L
JL
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D005587:Fowlpox virus / Q000235:genetics / Q000276:immunology; D005822:Genetic Vectors; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D008297:Male; D017430:Prostate-Specific Antigen / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D014615:Vaccinia / Q000235:genetics / Q000276:immunology
D019496:Cancer Vaccines; D011993:Recombinant Fusion Proteins; D017430:Prostate-Specific Antigen